Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824295 | 0.82 | KDM5A (0.37) | MEN1KMT2AKDM5AGSK3BDYRK1A | |
| SCHEMBL12234490 | 0.79 | MEN1 (0.36) | MEN1KMT2AKDM5AGSK3BDYRK1A | |
| SCHEMBL19356955 | 0.79 | GABRG2 (0.38) | KDM5A | |
| SCHEMBL5591480 | 0.79 | NOTUM (0.52) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL20267494 | 0.78 | ALDH1A1 (0.44) | KDM4ENPC1RAB9A | |
| SCHEMBL11325822 | 0.77 | MEN1 (0.47) | MEN1KMT2AMAPK1SYKKDM4E | |
| SCHEMBL1614140 | 0.77 | — | — | |
| SCHEMBL170374 | 0.77 | — | — | |
| SCHEMBL2282033 | 0.77 | CPB2 (0.45) | MEN1KMT2AMAPK1KDM5A | |
| SCHEMBL1662858 | 0.76 | BAZ2B (0.46) | KDM5ASYKGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920169-A | N-indolyl imidazole carboxamide compound and preparation method and application thereof | 中国医科大学 | 2021-06-08 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | PAYNE LINDA S (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1196384-A4 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1196384-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000578-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0154132-B1 | 6-ALKYLIDENE PENEMS, THEIR PREPARATION AND USE, AND INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1992-01-08 | — | — | EP | disclosed |
| US-4853027-A | PREEMGENCE, POSTEMERGENCE HOERBICIDES; WEEDS, GRASSES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
| US-4798828-A | LACTAMASE INHIBITORS | BEECHAM GROUP P.L.C. (GB) | 1989-01-17 | — | — | US | disclosed |
| EP-0154132-A1 | 6-Alkylidene penems, their preparation and use, and intermediates | BEECHAM GROUP PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | MEN1 2296/4885KMT2A 4186/4885MAPK1 116/4885 |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | MEN1 1404/4885KMT2A 227/4885MAPK1 2367/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | MEN1 3635/4885KMT2A 4318/4885MAPK1 343/4885 |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | CYP2S1, IMPDH1, IDO1 | MEN1 4377/4885KMT2A 3589/4885MAPK1 2095/4885 |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NOD1, NLRP3, CASP1 | MEN1 1374/4885KMT2A 3161/4885MAPK1 1314/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | MEN1 2667/4885KMT2A 203/4885MAPK1 215/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | MEN1 722/4885KMT2A 3227/4885MAPK1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.